Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8931 + Paclitaxel in Metastatic Gastric Cancer
NCT01579578Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing AZD8931 + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Change in Tumour Size at 8 Weeks. Started Apr 2012; status: terminated.
02
Drugs
sapitinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01579578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01579578.